Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
ConclusionsBP elevations following esketamine dosing are generally transient, asymptomatic, and not associated with serious cardiovascular safety sequalae. Further evaluation of long-term cardiovascular outcomes is warranted.
Source: CNS Drugs - Category: Neurology Source Type: research
More News: Cardiology | Cardiovascular | Depression | Electrocardiogram | Heart | Hypertension | Neurology | Study